Cocrystal Pharma (COCP) Return on Capital Employed (2011 - 2026)
Cocrystal Pharma (COCP) reported Return on Capital Employed of 142.49% for Q1 2026, up 1611.0% on a YoY basis from 8.33% in Q1 2025, and down 24.32% sequentially from 114.61% in Q4 2025.
Cocrystal Pharma (COCP) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cocrystal Pharma (COCP) has 14 years of Return on Capital Employed data on file, last reported at 142.49% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1611.0% year-over-year to 142.49%; the trailing twelve-month figure through Mar 2026 stood at 142.49% (up 1611.0% YoY), and the FY2025 full-year result was 96.21%, down 651.0% from the prior year.
- Return on Capital Employed declined to 142.49% in Q1 2026, from 114.61% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.69% in Q1 2022 to a low of 164.12% in Q2 2025.
- A 5-year average of 97.27% and a median of 92.39% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 4340 bps in 2024 and sank 9222 bps in 2025, its largest moves.
- Tracing COCP's Return on Capital Employed over 5 years: stood at 92.39% in 2022, then increased by 30 bps to 64.72% in 2023, then tumbled by 122 bps to 143.99% in 2024, then increased by 20 bps to 114.61% in 2025, then slipped by 24 bps to 142.49% in 2026.
- Business Quant data shows COCP's Return on Capital Employed at 142.49% in Q1 2026, 114.61% in Q4 2025, and 122.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Cocrystal Pharma | 12.57 Mn | 7.74 Mn | - | -142.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -142.49% |
| Dec 31, 2025 | -114.61% |
| Sep 30, 2025 | -122.78% |
| Jun 30, 2025 | -164.12% |
| Mar 31, 2025 | -158.60% |
| Dec 31, 2024 | -143.99% |
| Sep 30, 2024 | -113.91% |
| Jun 30, 2024 | -87.43% |
| Mar 31, 2024 | -66.38% |
| Dec 31, 2023 | -64.72% |
| Sep 30, 2023 | -56.56% |
| Jun 30, 2023 | -55.38% |
| Mar 31, 2023 | -109.78% |
| Dec 31, 2022 | -92.39% |
| Sep 30, 2022 | -80.24% |
| Jun 30, 2022 | -59.43% |
| Mar 31, 2022 | -20.69% |
| Dec 31, 2021 | -17.90% |
| Sep 30, 2021 | -14.31% |
| Jun 30, 2021 | -15.74% |